Characteristics and treatment outcomes of patients with multi-drug-resistant tuberculosis at Abbassia Chest Hospital
Abstract
Multi-drug-resistant tuberculosis (MDR-TB) remains a significant health concern. This study analyzes patients admitted to Abbassia Chest Hospital, focusing on their characteristics, drug resistance patterns, treatment outcomes, and risk factors for poor prognosis. A retrospective cohort study was conducted on 121 patients admitted to the MDR unit at Abbassia Chest Hospital. TB diagnosis was confirmed using sputum smear microscopy, microbiological culture and sensitivity testing, and molecular methods (GeneXpert). Patient data were extracted from hospital records for statistical analysis. The mean age of MDR-TB patients was 40 years, with 75.21% being male. Key risk factors included prior TB interrupted treatment, smoking, and contact with MDR-TB patients. Resistance rates exceeded 90% for cycloserine, ethionamide, pyrazinamide, and levofloxacin, while 71.9% were resistant to amoxicillin. Sputum conversion occurred in 95.04% of patients, with a mean conversion time of 2.21 ± 1.44 months. Successful treatment was achieved in 84.3% of cases, while 45.45% experienced side effects, the most common being hyperuricemia (28.1%), gastritis, and ototoxicity (11.57% each). Bad prognosis was associated with comorbidities like ischemic heart disease (OR 15.34, p = 0.02) and delayed sputum conversion (OR 1.63/month, p = 0.03). Side effects were not linked to bad outcomes. While most MDR-TB patients achieved successful treatment outcomes, certain factors, such as comorbidities…
How strong is the evidence?
Evidence Hub reads this as a cohort study, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 121 participants or records.
Read the paper
Related studies
- Ferulic acid regulates the AKT/GSK-3β/CRMP-2 signaling pathway in a middle cerebral artery occlusion animal model
- Novel Pharmacokinetic/Pharmacodynamic Parameters Quantify the Exposure–Effect Relationship of Levofloxacin against Fluoroquinolone-Resistant Escherichia coli
- Photochemical behavior of levofloxacin
- Correlation Between Dissolution Profiles of Salt-Form Drugs in Biorelevant Bicarbonate Buffer and Oral Drug Absorption: Importance of Dose/ Fluid Volume Ratio
- Evaluation of the synergistic potential and mechanisms of action for de novo designed cationic antimicrobial peptides
- Synthesis of [11C]levofloxacin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.